CRP reductions in participants with obesity and elevated baseline inflammation BGE-102 was well tolerated across all dose levels Phase 2 proof-of-concept trial in cardiovascular risk planned to ...

BioAge Labs (NASDAQ:BIOA) executives outlined phase I results for its oral, brain-penetrant NLRP3 inhibitor BGE-102, ...

The company has rallied from an earlier setback in obesity thanks to early progress for a drug targeting “NLRP3,” an ...

BioAge Labs said its investigational pill for cardiovascular risk prevention significantly reduced inflammation in an early ...

(Reuters) -BioAge Labs is eyeing a valuation of up to $639.7 million in its upsized initial public offering in the United States, the obesity drug developer said on Wednesday, in a sign of strong ...

BioAge Labs Inc BIOA shares are up on Tuesday after the company reported positive Phase 1 data for BGE-102, an oral NLRP3 ...

Shares of BioAge Labs were higher after the company shared positive data for a trial of its drug as a treatment for inflammation. The stock gained 9% to $20.49 in pre-market trading Tuesday. Through ...

Sept 26 (Reuters) - Shares of BioAge Labs (BIOA.O), opens new tab opened 25% above their initial public offering price on Thursday in a strong debut for the weight-loss drug developer against the ...

BioAge is making its way into the race among drug companies to target inflammation as a way to treat chronic conditions.

Interest in metabolic medicines is riding high, led by the popular class of weight management drugs known as GLP-1 agonists. BioAge Labs aims to help those medications work better with a lead drug ...

BioAge Labs (NASDAQ: BIOA) is a small drugmaker whose shares have caught fire this year. The company has made clinical progress in the hottest therapeutic area in the industry right now: Weight ...